Human Renal Cell Cancer Proliferation in Tissue Culture Is Tonically Inhibited by Opioid Growth Factor

Bisignani, Geoffrey; McLaughlin, Patricia J.; Ordille, Sarah; Beltz, M. Scott; Jarowenko, Mark V.; Zagon, Ian S.

doi:10.1016/s0022-5347(05)68157-8

Cited by 49 publications

(45 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The opioid growth factor (OGF) ([Met 5 ]-enkephalin) and its receptor, OGFr, have been well documented in the regulation of growth of a variety of human cancer cells in culture (1)(2)(3)(4)(5) and tumors in nude mice (6)(7)(8)(9). OGF serves as an autocrineproduced, endogenous pentapeptide that inhibits cell proliferation in a receptor-mediated manner (1)(2)(3)(4)(5)10).…”

Section: Introductionmentioning

confidence: 99%

“…OGF serves as an autocrineproduced, endogenous pentapeptide that inhibits cell proliferation in a receptor-mediated manner (1)(2)(3)(4)(5)10). OGF activity is not related to apoptosis/necrosis (11) or differentiation (12), and acts in an anchorage-independent manner (13).…”

Section: Introductionmentioning

confidence: 99%

“…The mechanism of action appears to be that OGF upregulates the cyclindependent kinase inhibitor pathway in order to delay the G 0 /G 1 phase of the cell cycle (14). OGF and OGFr have been demonstrated by immunohistochemistry, radioimmunoassay, and/or receptor binding to be present in a variety of human and animal tumors and cancer cell lines (1)(2)(3)(4)(5)8,(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor

McLaughlin

Zagon

2006

Int J Oncol

View full text Add to dashboard Cite

Abstract. Opioid growth factor (OGF) is a native opioid peptide ([Met 5 ]-enkephalin) that interacts with the OGF receptor (OGFr). OGF serves as a tonically active negative growth factor in neoplasia, and the OGF-OGFr axis contributes to the maintenance of an equilibrium in cell proliferation by targeting the cyclin-dependent inhibitory kinase pathway. To inquire whether the expression of OGFr is related to tumor progression, cell lines of human squamous cell carcinoma of the head and neck (SCCHN) were transplanted into nude mice, and small, medium, and large tumors were assessed for OGFr by receptor binding assays and quantitative immunohistochemistry, and for gene expression of OGFr mRNA. Large tumors had a reduction of 3-to 7-fold in OGFr binding sites relative to small tumors, and medium size tumors showed a progressive diminishment in OGF receptors that ranged between that of small and large neoplasias. Tumors with xenografts of three different cell lines of SCCHN, representing poorly-and well-differentiated cancers, exhibited similar results. Quantitative densitometric immunohistochemistry revealed data comparable to receptor binding assays. Receptor affinity and the gene expression of OGFr mRNA were unchanged in tumors of different sizes. These data demonstrate that OGFr is reduced in SCCHN with tumor progression and that translation/ posttranslation of OGFr protein, but not transcriptional levels of the OGFr gene, is (are) involved. The attenuated levels of OGFr binding capacity may serve as a marker of SCCHN. These subnormal levels of OGFr may diminish the efficacy of the OGF-OGFr axis in maintaining cell proliferative activity, and contribute to more active cell replication. Gene therapy to reinstate more OGFr, and thus enhance OGFr function, could serve as a useful treatment for inhibiting tumor progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor

McLaughlin

Zagon

2006

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…If unresponsive to sedation, administer intravenous nitroprusside. 6 For hypotension, administer intravenous fluids and place in Trendelenburg position. If unresponsive to these measures, administer dopamine or norepinephrine.…”

Section: Note To Physiciansmentioning

confidence: 99%

“…VIVITROL should be administered by intramuscular (IM) injection into the gluteal muscle, and care must be taken to avoid inadvertent injection into a blood vessel (see DOSAGE AND ADMINISTRATION). Includes the preferred terms: anxiety NEC; anxiety aggravated; agitation; obsessive compulsive disorder; panic attack; nervousness; post-traumatic stress 6 Includes the preferred terms: malaise; fatigue (these two comprise the majority of cases); lethargy; sluggishness 7 Includes the preferred terms: muscle cramps; spasms; tightness; twitching; stiffness; rigidity 8 Includes the preferred terms: rash NOS; rash papular; heat rash 9 Includes the preferred terms: headache NOS; sinus headache; migraine; frequent headaches…”

Section: Retinal Artery Occlusionmentioning

confidence: 99%

Ocular safety of Topical Naltrexone

Sassani¹,

Liang²,

Bowie³

2011

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTDuring the past year we have obtained approval from our institutional and University Conflict of Interest Committees, which limited the ability of Dr. Sassani to actively participate in data collection or interpretation in the study. In order to compensate for this reduction in effective researchers, Dr. Esther Bowie, an Ophthalmologist on the faculty of our Department of Ophthalmology, will assist Dr. David Liang in performing the clinical studies and data collection.To date we have completed our first cohort of 4 volunteers at the once daily, 1 x 10-6 dosage, of topical Naltrexone in Vigamox® eyedrops in one eye of each volunteer. No untoward side effects were noted in this group of volunteers. We also have recruited and treated three patients for the second cohort who have completed the treatment schedule. We need to recruit one more volunteer for this cohort and complete the other three cohorts.We are committed to completing the study, and have requested a one year extension of the grant period with no additional funds in order to complete our study. Dr. Sassani and his associates have been funded to perform a Phase I Clinical Trial of Naltrexone dissolved in Vigamox® and applied topically as eye drops preliminary to a therapeutic trial of that medication in the treatment of corneal epithelial defects in diabetic individuals. During the past year, we have obtained Institutional and University Conflict of Interest approval for our study. As a result, Dr. Sassani has elected not to participate directly in data collection for the study. We have recruited Dr. Esther Bowie, an Ophthalmologist in the Department of Ophthalmology to assist Dr. Liang in volunteer examination and data collection. The recruitment of Dr. Bowie, who has a clinic schedule that complements that of Dr. Liang, should facilitate the examination of volunteers. SUBJECT TERMS Body:Background: Over the past 18 years, Dr. Sassani has worked with Dr. Zagon's research team delineating the role of the Opioid Growth Regulatory System in corneal epithelial homeostasis and wound healing. We have demonstrated that the native opioid peptide, [Met 5 ]-enkephalin, termed opioid growth factor (OGF) is a tonically active, rece...

show abstract

Cell size‐proliferation relationship in rat glioma cells

Rouzaire‐Dubois

Malo

Milandri

et al. 2003

Glia

View full text Add to dashboard Cite

The homeostasis of the central nervous system is highly controlled by glial cells and is dramatically altered in the case of glioma. In this respect, the complex connection between cell size and division is of particular importance and needs clarifying. In order to investigate this connection, cell number and volume were measured in C6 rat glioma cells under different experimental conditions, including continuous cell culture, Cl- channel blockade, and anisotonicity, and in the presence of an inhibitory conditioned medium collected from cell cultures or in a medium containing a low level of fetal calf serum. The rate of cell proliferation changed with cell volume in a bell-shaped manner, so that it is optimal within a cell volume window and appears to be controlled by low and high cell size checkpoints. The cell size-proliferation relationship can be defined by Boltzmann-like equations, which may reflect the effects of macromolecular crowding on proteins controlling the cell cycle progression. Altogether, these observations indicate that glioma cell proliferation is controlled predominantly but not exclusively by cell size-dependent mechanisms.

show abstract

Human Renal Cell Cancer Proliferation in Tissue Culture Is Tonically Inhibited by Opioid Growth Factor

Abstract: OGF tonically inhibits renal cancer cell proliferation in tissue culture, and may play a role in the pathogenesis and management of human renal cell cancer.

Cited by 49 publications

References 10 publications

Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor

Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor

Ocular safety of Topical Naltrexone

Cell size‐proliferation relationship in rat glioma cells

Contact Info

Product

Resources

About